Literature DB >> 9128302

Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients.

J Labenz1, B Tillenburg, U Peitz, G Börsch, J P Idström, E Verdú, M Stolte, A L Blum.   

Abstract

OBJECTIVE: We have previously shown that, in duodenal ulcer patients, pH control by omeprazole is less pronounced after cure of Helicobacter pylori infection. The present study was designed to test the hypothesis that this response to omeprazole persists 1 yr after cure of H. pylori infection.
METHODS: In 12 duodenal ulcer patients, intragastric acidity was measured with a glass electrode during treatment with omeprazole (20 mg) once daily before, and 4-6 wk and 1 yr after, cure of H. pylori infection. H. pylori infection was assessed by [13C]urea breath test, culture, histology (Warthin Starry stain), and rapid urease test.
RESULTS: Cure of H. pylori infection resulted in a lowered pH during omeprazole treatment. This effect persisted after 1 yr. Median 24-h gastric pH before H. pylori treatment was 5.6; 4-6 wk after cure of the infection it was 2.9 (p = 0.003), and 1 yr after cure of the infection it remained unchanged (pH = 2.5; p = 0.5). Accordingly, twice as much time was spent above pH 3 and pH 4 before H. pylori treatment than 1 or 12 months after cure (percent of time > or = pH 3: 82.7 vs. 49.7 vs. 43.1; percent of time > or = pH 4: 72.7 vs. 38.3 vs. 26.4).
CONCLUSION: In duodenal ulcer patients, cure of H. pylori infection resulted in a marked rapid and persistent decrease of the pH increasing effect of omeprazole. Therefore, H. pylori is a determinant of the pH achieved in response to omeprazole treatment in duodenal ulcer patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9128302

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

1.  Gastroesophageal reflux and Helicobacter pylori: a review.

Authors:  F Pace; G Bianchi Porro
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

Review 2.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor?

Authors:  J Labenz; P Malfertheiner
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

Review 4.  Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors.

Authors:  Bjarni Thjodleifsson
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 5.  Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients.

Authors:  Corrado Blandizzi; Marco Tuccori; Rocchina Colucci; Giovanni Gori; Matteo Fornai; Luca Antonioli; Narcisa Ghisu; Mario Del Tacca
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

6.  Increased reflux symptoms after calcium carbonate supplementation and successful anti-Helicobacter pylori treatment.

Authors:  Lori A Fischbach; Pelayo Correa; Mark Feldman; Elizabeth Fontham; Elisa Priest; Karen J Goodman; Rajeev Jain
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

7.  Heartburn issues burnt out?

Authors:  Kentaro Sugano
Journal:  J Gastroenterol       Date:  2005-11       Impact factor: 6.772

Review 8.  Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease.

Authors:  E J Kuipers; E C Klinkenberg-Knol; S G Meuwissen
Journal:  Yale J Biol Med       Date:  1999 Mar-Jun

9.  Gastroesophageal Reflux Disease: A Population Based Study.

Authors:  Sylvester Nwokediuko
Journal:  Gastroenterology Res       Date:  2009-05-20

10.  Pilot, Randomized, Blinded, Placebo-Controlled Trial Investigating the Correlation Between Acid Control and Heartburn Relief with 14 Days of Esomeprazole Treatment.

Authors:  Philip B Miner; David A Johnson; Philip O Katz; Jing Li; Sergio C Gatoulis; Charles Pollack
Journal:  Adv Ther       Date:  2018-09-25       Impact factor: 3.845

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.